Navigation Links
VIVUS Reports Topline Findings From FORTRESS
Date:12/21/2011

he "Similar Medical Profile Cohort"). The Similar Medical Profile Cohort contained 13,614 dyads. In the Total Topiramate, Formerly Exposed, and Similar Medical Profile Cohorts there were 7, 21 and 9 oral clefts, respectively, for a prevalence of 0.36%, 0.16%, and 0.07%. Prevalence ratios standardized by center were 2.36 (95% CI: 0.99-5.59) for Total Topiramate Cohort versus the Formerly Exposed Cohort, and 5.44 (95% CI: 2.03-14.61) for Total Topiramate Cohort versus Similar Medical Profile Cohort. Results standardized by propensity score and site as well as results adjusting for other covariates, one at a time, yielded very similar results. One data source reported an unexpectedly low prevalence of oral clefts in the Similar Medical Profile Cohort.  To evaluate this finding, investigators conducted post-hoc analyses that involved repeated re-sampling from the group of dyads who were eligible for this cohort.  Based on this re-sampling, the investigators determined that the oral clefts prevalence observed in the cohort was likely an artificially low estimate due to random error, suggesting that the observed prevalence ratio for the Total Topiramate Cohort versus the Similar Medical Profile Cohort is an over-estimate.

As part of FORTRESS, Major Congenital Malformations, or MCMs, are being evaluated. The MCM analysis is ongoing.  The FORTRESS findings are based on a claims-only analysis.  All of the results of the study are considered to be preliminary until the results are validated. The results will be final when validation is completed, which is expected in the third quarter of 2012.

About Qnexa
Qnexa [kyoo-nek-suh] is an investigational drug candidate being developed to address weight loss, type 2 diabetes and obstructive sleep apnea. Qnexa is a once-a-day, proprietary, oral, controlled-release formulation of low-dose phentermine and topiramate, which is designed to decrease appetite and increas
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. VIVUS to Present at the Credit Suisse 2011 Healthcare Conference
2. VIVUS Resubmits Qnexa NDA to the FDA
3. VIVUS Provides Regulatory Update on QNEXA
4. VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction
5. VIVUS Announces $45.8 Million Registered Direct Offering of Common Stock
6. VIVUS Reports Second Quarter and First Six Months 2011 Financial Results
7. VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
8. VIVUS to Present at Three Upcoming Investor Conferences in March
9. VIVUS Provides Regulatory Update on QNEXA NDA
10. VIVUS to Present at the 2011 JP Morgan Healthcare Conference
11. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... Aug. 3, 2015  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... TELESTAR Phase 3 clinical trial met its primary ... in treating cancer patients with carcinoid syndrome that ... of care. Telotristat etiprate was discovered using Lexicon,s ... is the company,s first discovery to complete a ...
(Date:7/31/2015)... 31, 2015 Today, the National Association ... ) issued a report urging greater accountability by ... taken against websites illegally selling medications online. As ... Identification Program Progress Report for State and Federal ... of websites illegally distribute medications and avoid retribution. ...
(Date:7/31/2015)... TAMPA, Fla. , July 31, 2015 /PRNewswire/ ... announced today that it has made a structured ... -based company specializing in milling, micronization and ... investment will help grow Powdersize,s business while simultaneously ... solutions to Xcelience,s portfolio of capabilities. ...
Breaking Medicine Technology:Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 3Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3
... Perrigo Company (Nasdaq: PRGO ; TASE) and its ... tentative approval from the U.S. Food and Drug Administration for ... a generic version of UCB,s Xyzal® Oral Solution. Synthon believes ... generic that can entitle it to 180 days of generic ...
... -- Concord Medical Services Holdings Limited ("Concord Medical" ... of the largest network of radiotherapy and diagnostic imaging centers ... the first quarter ended March 31, 2011 (1). ... Total net revenues in the first quarter of 2011 ...
Cached Medicine Technology:Perrigo's Partner Synthon Receives FDA Tentative Approval for Levocetirizine Solution - Generic Equivalent to Xyzal® Oral Solution 2Perrigo's Partner Synthon Receives FDA Tentative Approval for Levocetirizine Solution - Generic Equivalent to Xyzal® Oral Solution 3Concord Medical Announces First Quarter 2011 Financial Results 2Concord Medical Announces First Quarter 2011 Financial Results 3Concord Medical Announces First Quarter 2011 Financial Results 4Concord Medical Announces First Quarter 2011 Financial Results 5Concord Medical Announces First Quarter 2011 Financial Results 6Concord Medical Announces First Quarter 2011 Financial Results 7Concord Medical Announces First Quarter 2011 Financial Results 8Concord Medical Announces First Quarter 2011 Financial Results 9Concord Medical Announces First Quarter 2011 Financial Results 10Concord Medical Announces First Quarter 2011 Financial Results 11Concord Medical Announces First Quarter 2011 Financial Results 12Concord Medical Announces First Quarter 2011 Financial Results 13
(Date:8/2/2015)... ... August 03, 2015 , ... A new Phase I research study is ... study is led by Kenneth G. Lucas, M.D. , chief of the division ... with colleagues at Kosair Children’s Hospital and in the UofL Department ...
(Date:8/1/2015)... ... 2015 , ... Back packs can be dangerous? Whaaat?! , Not the danger ... havoc on a kid's spine. With school starting again, most kids will be asking ... you are aware of how to help them prevent injuries by understanding backpack safety. ...
(Date:8/1/2015)... ... 01, 2015 , ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural ... by the National Retail Federation, the largest retail trade association in the world, for ... business owners to be named as such. According to the NRF’s website, Retail Champions ...
(Date:8/1/2015)... Dallas, TX (PRWEB) , ... August 01, 2015 , ... ... support for the March4thforWellBeing foundation, making hers the very first small business donation to ... and look beautiful for over thirty years. Her legacy includes a complete line of ...
(Date:7/31/2015)... ... 2015 , ... When the weather turned hot and warm-season turfgrasses, such as ... called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for short. Incidentally, both names ... new type of sod, Super-Sod is giving away red Adirondack chairs with the Leisure ...
Breaking Medicine News(10 mins):Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Local Retail Advocate Wins National Recognition 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2
... an increased risk of death, by about 12 to 16% ... said a new research published in the latest issue of ... Neonatal and Developmental Medicine, Stanford University, who had done the ... their first month of life than later. Researchers have done ...
... Reddy Saturday administered a "defeat AIDS pledge"// to people ... ,India has 5.13 million people infected with HIV/AIDS. ... in the country with more than 400,000 affected people. ... HIV prevalence rate is an alarmingly 2.25 percent among ...
... easier to diagnose strokes affecting the left-brain than the ... of The Lancet.// ,The authors state that discrepancy ... of right-brain stroke. ,Cerebrovascular events are frequently accompanied ... the brain the lesion occurs. People with events on ...
... it can be marketed as functional food ingredients, or even ... have been able to identify the molecular structure of ... of different flavonols. They also say that they are able ... compounds tailored to specific needs. , ,Several studies in ...
... appears in the current edition of The Lancet said ... high risk from becoming infertile.//, ,Female genital mutilation ... World Health Organization estimates that more than 132 million ... that about 2million procedures are done every year. Few ...
... drug users and HIV infection was done by Chris ... Health. The results of the study showed that an ... countries of Afghanistan to Eastern Europe. “This HIV/AIDS ... ahead of our responses,” says Chris Beyrer. “Drug treatment ...
Cached Medicine News:Health News:"Defeat AIDS Pledge" by Andhra CM 2Health News:Stroke In The Right-Brain Can Remain Undiagnosed 2Health News:Girls Who Undergo Genital Mutilation Can Become Infertile 2Health News:HIV Infection Higher In Drug Trafficking Countries 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: